OpenAlex
PricingAboutJobs
Log inGet started
Work

A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer

HTML

Year: 2004
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-03-0406
Authors: Lynn Van Ummersen, Kim Binger, Jennifer Volkman, Rebecca Marnocha, Kendra Tutsch, Jill Kolesar, Rhoda Arzoomanian, Dona Alberti, George Wilding
Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center
Language: English

Topic: PI3K/AKT/mTOR signaling in cancer
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: perifosine, alkylphosphocholines, maximum tolerated dose, dose-limiting toxicity, gastrointestinal toxicity, 5-HT3 receptor antagonists, pharmacokinetics, advanced solid tumors, sarcoma, renal cell carcinoma, anticancer activity
SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute
Award: Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)
OpenAlex ID: W2105092450
FWCI: 5.389
Cites: 9
Cited by: 171
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms